The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on INSM stock, giving a Buy rating on November 5. Graig ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

The results were quite promising, as Prof. Hyun remarks, "Inhibiting the activity of ubiquitin specific peptidase 14 (USP14), ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

dipeptidyl-peptidase-4 inhibitors (DPP-4i), and other GLP-1RAs (which mimic the effects of GLP-1s). Patients prescribed semaglutide had a 40% to 70% reduced risk of first-time Alzheimer’s ...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed (INSM – Research Report), with a price ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

For patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and diabetes, treatment with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) may protect against ...

Semaglutide, the active ingredient in Ozempic and Wegovy, may also help lower the risk of developing Alzheimer’s disease in people living with type 2 diabetes.